Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 20/20 | 0.64 |
| ▸ | BRD2 | P25440 | 1/20 | 0.58 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.58 |
| ▸ | TSPO | P30536 | 1/20 | 0.58 |
| ▸ | EP300 | Q09472 | 1/20 | 0.58 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.58 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16739108 | 0.89 | BRD4 (0.65) | BRD4BRD2ADORA2BTSPOEP300 | |
| SCHEMBL16738734 | 0.87 | BRD4 (0.73) | BRD4BRD2ADORA2BTSPOEP300 | |
| SCHEMBL16738061 | 0.84 | BRD4 (0.64) | BRD4BRD2ADORA2BTSPOEP300 | |
| SCHEMBL23436641 | 0.82 | BRD4 (0.76) | BRD4BRD2ADORA2BTSPOEP300 | |
| SCHEMBL23436760 | 0.80 | BRD4 (0.77) | BRD4BRD2ADORA2BTSPOEP300 | |
| SCHEMBL15069293 | 0.79 | BRD4 (0.76) | BRD4BRD2ADORA2BTSPOEP300 | |
| SCHEMBL16738708 | 0.79 | BRD4 (0.77) | BRD4BRD2ADORA2BTSPOEP300 | |
| SCHEMBL20384227 | 0.78 | BRD4 (0.74) | BRD4BRD2ADORA2BTSPOEP300 | |
| SCHEMBL20384379 | 0.78 | BRD4 (0.73) | BRD4BRD2ADORA2BTSPOEP300 | |
| SCHEMBL20384563 | 0.78 | BRD4 (0.73) | BRD4BRD2ADORA2BTSPOEP300 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015081246-A1 | BICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION (US) | 2015-06-04 | — | — | WO | claimed |
| US-20150148372-A1 | BICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION (US) | 2015-05-28 | — | — | US | claimed |
| WO-2015081246-A1 | BICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION (US) | 2015-06-04 | — | — | WO | disclosed |
| WO-2015081246-A1 | BICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION (US) | 2015-06-04 | — | — | WO | disclosed |
| US-20150148372-A1 | BICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION (US) | 2015-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150148372-A1 | BICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | BRD1, BRD3, BRD2 | BRD4 4/4885BRD2 3/4885ADORA2B 4334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.